Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danaher : Cytiva in U.S. Agreement to Expand Capacity for Covid-19 Vaccine-Related Items

10/13/2020 | 05:42pm EST

By Josh Beckerman

Danaher Corp.'s Cytiva unit will receive about $31 million under an agreement with the U.S. Department of Health and Human Services and Department of Defense to expand manufacturing capacity for products used to make Covid-19 vaccines.

Cytiva will produce items including liquid and dry powder cell culture media, cell culture buffers, mixer bags and XDR bioreactors.

Cytiva will expand manufacturing capacity in its Massachusetts facilities and create duplicate capabilities in its Utah facilities, HHS said.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-13-20 1942ET

All news about DANAHER CORPORATION
11/25DANAHER : to Present at Evercore ISI HealthCONx Conference
AQ
11/24DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
11/23DANAHER : Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antib..
PR
11/17DANAHER : to Present at Wolfe Research Healthcare Conference
AQ
11/16DANAHER : To Present At Wolfe Research Healthcare Conference
PR
11/11DANAHER : Releases 2020 Sustainability Report
AQ
11/10DANAHER : Releases 2020 Sustainability Report
PR
11/10DANAHER : Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries..
PR
10/27DANAHER : Cytiva strengthens support to diagnostics industry with new labs, serv..
AQ
10/23DANAHER : Reports Third Quarter 2020 Results
AQ
More news
Financials (USD)
Sales 2020 21 954 M - -
Net income 2020 3 384 M - -
Net Debt 2020 15 370 M - -
P/E ratio 2020 46,4x
Yield 2020 0,33%
Capitalization 154 B 154 B -
EV / Sales 2020 7,71x
EV / Sales 2021 6,61x
Nbr of Employees 60 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 249,50 $
Last Close Price 216,78 $
Spread / Highest target 29,2%
Spread / Average Target 15,1%
Spread / Lowest Target -36,3%
EPS Revisions
Managers
NameTitle
Rainer M. Blair President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Alan G. Spoon Independent Director
Walter G. Lohr Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DANAHER CORPORATION41.24%153 996
CERNER CORPORATION0.97%22 718
PERKINELMER, INC.33.12%14 474
GN STORE NORD A/S60.04%10 378
BRUKER CORPORATION-0.61%7 756
LIFETECH SCIENTIFIC CORPORATION102.01%1 827